Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features

Infectious Disease Clinics of North America

Volumn 33, Issue 4, 2019, Pages 869-889

  Hui, David S C ^a   Zumla, Alimuddin ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical; Coronavirus; Epidemic; Epidemiology; Prevention; SARS

Indexed keywords

CORTICOSTEROID DERIVATIVE; INTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; VACCINE;

AIRBORNE INFECTION; ANTIVIRAL THERAPY; BAT; CHINA; CIVET (ANIMAL); CLINICAL FEATURE; COMMUNITY CARE; CONVALESCENCE; DIARRHEA; ELECTROLYTE BALANCE; FECES; FEVER; FLUID THERAPY; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HISTORY; HOSPITAL INFECTION; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INCUBATION TIME; INFECTION CONTROL; INFLUENZA; INHALATION; INTENSIVE CARE; LABORATORY DIAGNOSIS; MORBIDITY; MORTALITY; MOUTH; NONHUMAN; OPPORTUNISTIC INFECTION; OXYGEN THERAPY; PATHOGENESIS; PREVALENCE; PROGNOSIS; RESPIRATORY TRACT DISEASE; REVIEW; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIROLOGY; VIRUS ENTRY; VIRUS TRANSMISSION; ZOONOSIS; GLOBAL HEALTH; PHYSIOLOGY;

GLOBAL HEALTH; HISTORY, 21ST CENTURY; HUMANS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 85073828407     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2019.07.001     Document Type: Review

References (100)

1. Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003;52:715-720.
2. WHO. List of blue print priority diseases. Accessed January7, 2019. Available at: https://www.who.int/blueprint/priority-diseases/en/
3. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003: 348:1977-1985.
4. Peiris JS, Lai ST, Poon LL, et al; SARS study group. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319-1325.
5. WHO. Summary of probable SARS cases with onset of illness from 1 November to 31 July 2003. Date last updated 31 Dec 2003. Date last Accessed January 10, 2016. Available at: http://www.who.int/csr/sars/country/table2004_04_21/en/
6. WHO. [Chapter 5]. SARS: Lessons from a new disease. The World Health Report 2003;pp71-78. Accessed January 10, 2016. Available at: http://www.who.int/whr/2003/en/whr03_en.pdf?ua=1
7. Zumla A, Chan JF, Azhar EI, et al. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327-347.
8. Drosten C, Gunther S, Preiser W, et al. Identification of a novel Coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-1976.
9. Ksiazek TG, Erdman D, Goldsmith CS, SARS Working Group. et al; A Novel Coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-1966.
10. Marra MA, Jones SJ, Astell CR, et al. The genome sequence of the SARS-associated coronavirus. Science 2003;300:1399-1404.
11. Ruan YJ, Wei CL, Ee LA, et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003;361:1779-1785.
12. Du L, Qiu JC, Wang M, et al. Analysis on the characteristics of blood serum Ab-IgG detective result of severe acute respiratory syndrome patients in Guangzhou, China. Zhonghua Liu Xing Bing Xue Za Zhi. 2004;25(11):925-928.
13. Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 2003;302:276-278.
14. Yu D, Li H, Xu R,Centers for Disease Control and Prevention (CDC) et al. CDC. Prevalence of IgG antibody to SARS-associated coronavirus in animal traders- Guangdong province, China, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:986-987.
15. Song HD, Tu CC, Zhang GW, et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A. 2005;102:2430-2435.
16. Wang M, Yan M, Xu H, et al. SARS-CoV infection in a restaurant from palm civet. Emerg Infect Dis. 2005;11:1860-1865.
17. Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A. 2005;102(39):14040-14045.
18. Li W, Shi Z, Yu M, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005;310:676-679.
19. Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007;170:1136-1147.
20. Chan PK, To KF, Lo AW, et al. Persistent infection of SARS coronavirus in colonic cells in vitro. J Med Virol 2004;74:1-7.
21. Simmons G, Gosalia DN, Rennekamp AJ, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A. 2005;102:11876-11881.
22. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450-454.
23. Hamming I, Timens W, Bulthuis ML, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631-637.
24. Leung WK, To KF, Chan PK, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology 2003;125:1011-1017.
25. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11:875-879.
26. Law PT, Wong CH, Au TC, et al. The 3a protein of severe acute respiratory syndrome-associated coronavirus induces apoptosis in Vero E6 cells. J Gen Virol. 2005;86(Pt 7):1921-1930.
27. Tan YJ, Fielding BC, Goh PY, et al. Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. J Virol. 2004;78:14043-14047.
28. Nicholls JM, Poon LL, Lee KC, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361:1773-1778.
29. Franks TJ, Chong PY, Chui P, et al. Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore. Hum Pathol 2003;34:743-748.
30. Tse GM, To KF, Chan PK, et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 2004;57:260-265.
31. Haagmans BL, Kuiken T, Martina BE, et al. Pegulated interferon-a protects type I pneumocytes against SARS coronavirus infection in macaques. Nat Med 2004;10:290-293.
32. Peiris JS, Chu CM, Cheng VC, HKU/UCH SARS Study Group. et al; Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361:1767-1772.
33. Cheng VC, Hung IF, Tang BS, et al. Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome. Clin Infect Dis 2004;38:467-475.41.
34. Wong CK, Lam CWK, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004;136:95-103.
35. Zhao J, Zhao J, Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010;84(18):9318-9325.
36. Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated type i interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181-193.
37. Totura AL, Whitmore A, Agnihothram S, et al. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. MBio. 2015;6:[pii:e00638-15].
38. Wang Y, Liu L. The membrane protein of severe acute respiratory syndrome coronavirus functions as a novel cytosolic pathogen-associated molecular pattern to promote beta interferon Induction via a toll-like-receptor-related TRAF3-independent mechanism. MBio. 2016;7(1). [pii:e01872-15]
39. Tang F, Liu W, Zhang F, et al. IL-12 RB1 genetic variants contribute to human susceptibility to severe acute respiratory syndrome infection among Chinese. PLoS One. 2008;3(5):e2183.
40. Ip WK, Chan KH, Law HK, et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis. 2005;191(10):1697-1704.
41. Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019 Feb 21;4(4). [pii:123158]. doi: 10.1172/jci.insight.123158. eCollection 2019 Feb 21.
42. Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome in Guangdong, People's Republic of China, in Feb 2003. Lancet 2003;362:1353-1358.
43. Hui DS, Sung JJ. Severe acute respiratory syndrome. Chest. 2003;124(1):12-15.
44. Peiris JS, Yuen KY, Osterhaus AD, et al. The severe acute respiratory syndrome. N Engl J Med 2003;349:2431-2441.
45. Lee N, Hui DS, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1986-1994.
46. Wong RS, Hui DS. Index patient and SARS outbreak in Hong Kong. Emerg Infect Dis 2004;10:339-341.
47. Loon SC, Teoh SC, Oon LL, et al. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol. 2004;88(7):861-863.
48. Yu IT, Wong TW, Chiu YL, et al. Temporal-spatial analysis of severe acute respiratory syndrome among hospital inpatients. Clin Infect Dis. 2005;40:1237-1243.
49. Xiao S, Li Y, Wong TW, et al. Role of fomites in SARS transmission during the largest hospital outbreak in Hong Kong. PLoS One. 2017;12(7):e0181558.
50. Booth TF, Kournikakis B, Bastien N, et al. Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis. 2005;191:1472-1477.
51. WHO. Update 95-SARS: Chronology of a serial killer.Accessed January 10, 2016. Available at: http://www.who.int/csr/don/2003_07_04/en.
52. Yu IT, Xie ZH, Tsoi KK, et al. Why did outbreaks of severe acute respiratory syndrome occur in some hospital wards but not in others? Clin Infect Dis. 2007;44:1017-1025.
53. Tran K, Cimon K, Severn M, et al. Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review. PLoS One. 2012;7:e35797.
54. Chu CM, Cheng VC, Hung IF, et al. Viral load distribution in SARS outbreak. Emerg Infect Dis. 2005;11:1882-1886.
55. Yu IT, Li Y, Wong TW, et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med. 2004;350:1731-1739.
56. Yu IT, Qiu H, Tse LA, et al. Severe acute respiratory syndrome beyond Amoy Gardens: completing the incomplete legacy. Clin Infect Dis. 2014;58:683-686.
57. Lloyd-Smith JO, Schreiber SJ, Kopp PE, et al. Superspreading and the effect of individual variation on disease emergence. Nature. 2005;438(7066):355-359.
58. Chiu WK, Cheung PCH, Ng KL, et al. Severe acute respiratory syndrome in children: Experience in a regional hospital in Hong Kong. Pediatr Crit Care Med 2003;4:279-283.
59. Donnelly CA, Ghani AV, Leung GM, et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003:361;1761-1766.
60. Leung GM, Hedley AJ, Ho LM, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med. 2004;141:662-673.
61. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003:289:2801-2809.
62. Chan JW, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with Severe acute respiratory syndrome (SARS). Thorax 2003;58:686-689.
63. Tsui PT, Kwok ML, Yuen H, et al. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg Infect Dis 2003;9:1064-1069.
64. Hung EC, Chim SS, Chan PK, et al. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. Clin Chem 2003;49:2108-2109.
65. Lau KK, Yu WC, Chu CM, et al. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis 2004;10:342-344.
66. Wong KC, Leung KS, Hui M. Severe acute respiratory syndrome (SARS) in a geriatric patient with a hip fracture. A case report. J Bone Joint Surg Am 2003;85A:1339-1342.
67. Hon KL, Leung CW, Cheng WT, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 2003;561:1701-1703.
68. Wong SF, Chow KM, Leung TN, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol. 2004;191:292-297.
69. Leung GM, Lim WW, Ho LM, et al. Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups. Epidemiol Infect 2006;134:211-221.
70. Hui DS, Wong PC, Wang C. SARS: clinical features and diagnosis. Respirology. 2003;8 Suppl:S20-S24.
71. Hui DS, Wong KT, Antonio GE, et al. Severe acute respiratory syndrome: correlation between clinical outcome and radiologic features. Radiology. 2004;233:579-585.
72. Pitzer VE, Leung GM, Lipstich M. Estimating variability in the transmission of severe acute respiratory syndrome to household contacts in Hong Kong, China. Am J Epidemiol 2007;166:355-363.
73. Poon LL, Chan KH, Wong OK, et al. Early diagnosis of SARS coronavirus infection by real time RT-PCR. J Clin Virol 2003;28:233-238.
74. Ng EK, Hui DS, Chan KC, et al. Quantitative analysis and prognostic implication of SARS coronavirus in the plasma and serum of patients with severe acute respiratory syndrome. Clin Chem 2003;49:1976-1980.
75. Ng EK, Ng PC, Hon KL, et al. Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. Clin Chem 2003;49:2085-2088.
76. Lee N, Chan PK, Ip M, et al. Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome. J Clin Virol. 2006;35:179-184.
77. Tang F, Quan Y, Xin ZT, et al. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011;186:7264-7268.
78. Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. Br Med J 2003;326:1358-1362.
79. Wong WM, Ho JC, Hung IF, et al. Temporal patterns of hepatic dysfunction and disease severity in patients with SARS. JAMA 2003;290:2663-2665.
80. Wong KT, Antonio GE, Hui DS, et al. Thin section CT of Severe Acute Respiratory Syndrome: Evaluation of 73 patients exposed to or with the disease. Radiology 2003;228:395-400.
81. Gomersall CD, Joynt GM, Lam P, et al. Short-term outcome of critically ill patients with severe acute respiratory syndrome. Intensive Care Med 2004; 30:381-387.
82. Shek CC, Ng PC, Fung GP, et al. Infants born to mothers with severe acute respiratory syndrome. Pediatrics 2003;112:e254-e256.
83. Sung JJ, Wu A, Joynt GM, et al. Severe Acute Respiratory Syndrome: report of treatment and outcome after a major outbreak. Thorax 2004;59:414-420.
84. Chu CM, Cheng VC, Hung IF; HKU/UCH SARS Study Group, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-256.
85. Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicenter retrospective matched cohort study. Hong Kong Med J 2003;9:399-406.
86. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon Alfacon-1 plus corticosteroids in severe acute respiratory syndrome. A Preliminary Study. JAMA 2003;290:3222-3228.
87. Fisman DN. Hemophagocytic syndrome and infection. Emerg Infect Dis 2000; 6:601-608.
88. Tsang OT, Chau TN, Choi KW, et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 2003;9:1381-1387.
89. Wang H, Ding Y, Li X, et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003; 349:507-508.
90. Griffith JF, Antonio GE, Kumta SM, et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 2005;235:168-175.
91. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31:304-309.
92. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343.
93. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44-46.
94. Soo Y, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10:676-678.
95. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Convalescent Plasma Study Group. et al; The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80-90.
96. Gao W, Tamin A, Soloff A, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003;362:1895-1896.
97. Zhao P, Ke JS, Qin ZL, et al. DNA vaccine of SARS-CoV S gene induces antibody response in mice. Acta Biochim Biophys Sin (Shanghai) 2004;36:37-41.
98. Yang ZY, Kong WP, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004;428:561-564.
99. Zhong NS, Zeng GQ. Pandemic planning in China: applying lessons from severe acute respiratory syndrome. Respirology. 2008;13 Suppl 1:S33-S35.
100. Seto WH, Conly JM, Pessoa-Silva CL, et al. Infection prevention and control measures for acute respiratory infections in healthcare settings: an update. East Mediterr Health J. 2013;19 Suppl 1:S39-S47.